Topic

Washington

A collection of 489 issues

How to Get Keytruda (Pembrolizumab) Covered by Cigna in Washington: Complete Guide to Prior Authorization, Appeals, and Cost Savings

Answer Box: Getting Keytruda Covered by Cigna in Washington Keytruda (pembrolizumab) requires prior authorization from Cigna and is typically dispensed through their specialty pharmacy, Accredo. First step: Your oncologist submits a PA request via CoverMyMeds or SureScripts with complete clinical documentation. If denied, you have 180 days to appeal internally,
5 min read

Myths vs. Facts: Getting Myozyme (Alglucosidase Alfa) Covered by UnitedHealthcare in Washington

Answer Box: Getting Myozyme Covered by UnitedHealthcare in Washington Eligibility: UnitedHealthcare requires prior authorization for Myozyme (alglucosidase alfa) with confirmed Pompe disease diagnosis via enzyme testing and genetic confirmation. Fastest path: Submit PA through UnitedHealthcare provider portal with comprehensive clinical documentation including specialist referral and diagnostic testing. First step today:
5 min read

How to Get Pemazyre (Pemigatinib) Covered by Aetna CVS Health in Washington: Appeals, Forms & Timelines

Answer Box: Getting Pemazyre Covered by Aetna CVS Health in Washington Pemazyre (pemigatinib) requires prior authorization from Aetna CVS Health and is typically non-formulary, requiring a formulary exception. Key requirements: FDA-approved test confirming FGFR2 fusion/rearrangement, previous systemic therapy failure, and comprehensive clinical documentation. First step: Have your oncologist submit
6 min read

How to Get Cometriq (Cabozantinib) Covered by UnitedHealthcare in Washington: Prior Authorization, Appeals, and Cost-Saving Strategies

Answer Box: Getting Cometriq Covered by UnitedHealthcare in Washington Fastest path to approval: Submit prior authorization through UnitedHealthcare's provider portal with complete medical records documenting medullary thyroid carcinoma diagnosis, progression status, and treatment history. If denied, pursue internal appeals (180 days) followed by Washington's Independent Review
4 min read